Synergistic photothermal ablative effects of functionalizing carbon nanotubes with a POSS-PCU nanocomposite polymer

Journal of Nanobiotechnology

Research

Aaron Tan¹  Seyed Yazdan Madani¹  Alexander M Seifalian²  Jayakumar Rajadas³  Giorgia Pastorin⁴ 

[1] Centre for Nanotechnology & Regenerative Medicine, UCL Division of Surgery & Interventional Science, University College London, NW3 2QG, London, UK;Centre for Nanotechnology & Regenerative Medicine, UCL Division of Surgery & Interventional Science, University College London, NW3 2QG, London, UK;Royal Free London NHS Foundation Trust Hospital, London, UK;Department of Neurology & Neurological Sciences, Biomaterials & Advanced Drug Delivery Laboratory, School of Medicine, Stanford University, California, USA;Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore;

关键词: Carbon nanotubes;    POSS-PCU;    Thermal ablation;    Nanotechnology;    Nanocomposite polymer;    Colorectal cancer;   

DOI  :  10.1186/1477-3155-10-34

 received in 2012-06-12, accepted in 2012-07-16,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundThe application of nanotechnology in biology and medicine represents a significant paradigm shift in the approach to the treatment of cancer. Evidence suggests that when exposed to near-infrared radiation (NIR), carbon nanotubes (CNTs) dissipate a substantial amount of heat energy. We have developed a novel nanocomposite polymer, polyhedral oligomeric silsesquioxane poly (carbonate-urea) urethane (POSS-PCU). POSS-PCU displays excellent biocompatibility and has been used in making artificial organs as well as protective coatings for medical devices.ResultsFunctionalizing (or “coating”) CNTs with POSS-PCU confers biocompatibility and increase the amount of heat energy generated, by enhancing dispersion. Here we demonstrate that POSS-PCU-functionalized multi-walled CNTs (MWNTs) act synergistically together when exposed to NIR to thermally ablate cancer cells.ConclusionGiven that POSS-PCU has already been used in human in first-in-man studies as trachea, lacrimal duct, bypass graft and other organs, our long-term goal is to take POSS-PCU coated CNTs to clinical studies to address the treatment of cancer by optimizing its therapeutic index and increasing its specificity via antibody conjugation.

【 授权许可】

Unknown   
© Tan et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.